Latest News and Press Releases

- Initiation of Phase 1/2 Clinical Trial Expected in Q1 2023 YONGIN, South Korea, December 13, 2022 -- 1ST Biotherapeutics, Inc., a clinical-stage biotechnology company focused on the development...

- Former GlaxoSmithKline and Proximagen executive adds to Rewind´s drug discovery and development expertise Leuven, Belgium, November 29, 2022 --- Rewind Therapeutics, a company developing...

- Significant expansion of allergy research expertise Geneva, Switzerland, November 23, 2022 – HpVac SA, a company developing novel preventive and therapeutic first-line therapies against...

- Former Head of Novartis' Ophthalmology Development Unit to provide significant product development expertise and industry network Berlin, Germany, November 16, 2022 --- Dopavision, a...

- Promising data presented at Protein and Antibody Engineering Summit (PEGS) - Multi-functional agent targeting three immune checkpoint receptors  - Potential as mono- and combination therapy for...

- Former Roche Head of Neuroimmunology strengthens Rewind´s neuroimmunology and neurodegeneration expertise Leuven, Belgium, October 19, 2022 --- Rewind Therapeutics, a company developing...

- Major milestone for accelerating the development of HpVac-13 in allergic diseases Geneva, Switzerland, October 18, 2022 – HpVac SA, a company developing novel preventive and therapeutic...

- Compound demonstrates excellent safety and tolerability in single ascending dose trial - Efficient penetration of blood-brain barrier YONGIN, South Korea, October 18, 2022 -- 1ST...

- Former Novartis director brings significant expertise in drug discovery and development Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – October 17, 2022 – ImmunOs Therapeutics...

Zahlreiche in der AAMBI-Studie identifizierte metabolische Biomarker in der BANON-Kohorte bestätigtPanel-Sensitivität von bis zu 89 % und Spezifität von bis zu 93 % in verblindeter...